Traditional Chinese herbal medicine in the supportive management of patients with chronic cytopaenic marrow diseases - A phase I/II clinical study

Complementary Therapies in Clinical Practice

Volumn 17, Issue 3, 2011, Pages 152-156

  Linn, Yeh ching ^a   Lu, Jiahui ^b   Lim, Lay cheng ^a   Sun, Huili ^a   Sun, Jue ^a   Zhou, Yongming ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b Yueyang Hospital   (China)

Author keywords

Aplastic anaemia; Myelodysplastic syndrome; Myelofibrosis; Quality of life; Traditional Chinese Medicine

Indexed keywords

HERBACEOUS AGENT;

ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHINESE MEDICINE; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; FEMALE; HUMAN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYTOTHERAPY; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, APLASTIC; CHRONIC DISEASE; COMORBIDITY; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHYTOTHERAPY; PRIMARY MYELOFIBROSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79960117491     PISSN: 17443881     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctcp.2011.01.004     Document Type: Article

References (35)

1. He M.D., Zhang S.F., Jiang S.Z. Effects of Fuzhengyangying granules on the bone marrow proliferation and bcl-2 expression in mice with immune mediated aplastic anemia. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007, 32:88-92.
2. Hui M.K., Wu W.K., Shin V.Y., So W.H., Cho C.H. Polysaccharides from the root of Angelica sinensis protect bone marrow and gastrointestinal tissues against the cytotoxicity of cyclophosphamide in mice. International Journal of Medical Sciences 2006, 3:1-6.
3. Liu W.J., Liu B., Guo Q.L., Zhang Y.C., Yuan Y.J., Fu X.D., et al. Influence of ganciclovir and Astragalus membranaceus on proliferation of hematopoietic progenitor cells of cord blood after cytomegalovirus infection in vitro. Zhonghua Er Ke Za Zhi 2004, 42:490-494.
4. Tian S.L., Zhou Y.M., Huang T., Xue Z.Z., He W. Effects of Yisui Jiedu recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia. Zhong Xi Yi Jie He Xue Bao 2008, 6:185-189.
5. Yang M., Chan G.C., Deng R., et al. An herbal decoction of radix astragali and radix angelicae sinensis promotes hematopoiesis and thrombopoiesis. Journal of Ethnopharmacology 2009, 124:87-97.
6. Zhu H.F., Wan D., Chen Y., Xu X.Y., Chen L., He Z.G. Effects of rehmannia root decoction serum on cell proliferation and EPO expression in cultured human umbilical vein endothelial cells. Zhongguo Zhong Yao Za Zhi 2008, 33:1579-1582.
7. Zhu X.L., Zhu B.D. Mechanisms by which Astragalus membranaceus injection regulates hematopoiesis in myelosuppressed mice. Phytotherapy Research 2007, 21:663-667.
8. Chen Y., Zhu B., Zhang L., Yan S., Li J. Experimental study of the bone marrow protective effect of a traditional Chinese compound preparation. Phytotherapy Research 2009, 23:823-826.
9. Wang M.S., Li J., Di H.X., et al. Clinical study on effect of astragalus injection and its immuno-regulation action in treating chronic aplastic anemia. Chinese Journal of Integrative Medicine 2007, 13:98-102.
10. Liu L., Shu X., Hu N.P. Effect of TCM syndrome-typing based therapy combined with cyclosporin in treating myelodysplastic syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006, 26:933-935.
11. Song S.H., Wu D.Y., Pang Y.H., Liu Q.C., Ma L.F. An observation of treatment outcome of Huasui pill in the treatment of 70 cases of primary myelofibrosis. Hebei Journal of Traditional Chinese Medicine 2006, 28:666.
12. Wang W.J., Wu Z.K., Zhang X.H., et al. Clinical observation of Yisui Shengxue granule in treating 25 patients with hemoglobin H disease. Zhong Xi Yi Jie He Xue Bao 2008, 6:153-156.
13. Wu Z.K., Liu Y.M., Zhang X.H., et al. Treatment of beta-thalassemia with Bushen Yisui therapy: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 2007, 5:137-140.
14. Yuan A., Liu C., Huang X. Treatment of 34 cases of chronic aplastic anemia using prepared Rehmannia polysaccharide associated with stanozolol. Zhongguo Zhong Xi Yi Jie He Za Zhi 1998, 18:351-353.
15. Zhou Y.M., Huang Z.Q., Huang T., et al. Clinical study of Shengxue mixture in treating aplastic anaemia. Chinese Journal of Integrative Medicine 2000, 20:173-175.
16. Zhou Y.M., Tian S.L., Huang Z.Q., et al. Clinical research on Shengxue concoction in the treatment of myelodysplastic syndrome. Traditional Chinese Medicine Journal 2006, 5:42-45.
17. Xu S., Hu X.M., Xu Y.G. Effect of treatment for myelodysplastic syndrome by Qinghuang powder combined with Chinese herbs for reinforcing shen and strenghening pi. Zhongguo Zhong Xi Yi Jie He Za Zhi 2008, 28:216-218.
18. Shih V., Chiang J.Y., Chan A. Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. Annals of Oncology 2009, 20:752-757.
19. Lim M.K., Sadarangani P., Chan H.L., Heng J.Y. Complementary and alternative medicine use in multiracial Singapore. Complementary Therapies in Medicine 2005, 13:16-24.
20. Lim J., Wong M., Chan M.Y., et al. Use of complementary and alternative medicine in paediatric oncology patients in Singapore. Annals Academy of Medicine, Singapore 2006, 35:753-758.
21. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
22. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
23. Schrezenmeier H., Bacigalupo A., Aglietta M., et al. Aplastic anemia, pathophysiology and treatment 2000, Cambridge University Press, Cambridge.
24. Osoba D., Rodrigues G., Myles J., Zee B., Pater J. Interpreting the significance of changes in health-related quality-of- life scores. Journal of Clinical Oncology 1998, 16:139-144.
25. Fayers P.M., Aaronson N.K., Bjordal K., Groenvold M., Curran D. Bottomley A on behalf of the EORTC quality of life group. The EORTC QLQ-C30 scoring manual 2001, Europen Organisation for Research and Treatment of Cancer.
26. Barosi G., Bordessoule D., Briere J., et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005, 106:2849-2853.
27. Camitta B.M. What is the definition of cure for aplastic anemia?. Acta Haematologica 2000, 103:16-18.
28. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
29. Dixit A., Chatterjee T.C., Mishra P., et al. Hydroxyurea in thalassemia intermedia - a promising therapy. Annals of Hematology 2005, 84:441-446.
30. Fang S., Wu Z., Zhang X., et al. Clinical observation on YiSuiShengXueGranule on treating 156 patients with beta-thalassemia major and the molecular mechanism study. Biological and Pharmaceutical Bulletin 2007, 30:2084-2087.
31. Available from: ; 2010. http://www.tcmlib.com.
32. Available from: ; 2010. http://alternativehealing.org/chinese_herbs_dictionary.htm.
33. Yan J., Engle V.F., He Y., Jiao Y., Gu W. Study designs of randomized controlled trials not based on Chinese medicine theory are improper. Chinese Medicine 2009, 4:3.
34. Tang J.L. Research priorities in traditional Chinese medicine. British Medical Journal 2006, 333:391-394.
35. Shea J.L. Applying evidence-based medicine to traditional Chinese medicine: debate and strategy. Journal of Alternative and Complementary Medicine 2006, 12:255-263.